VAERS Explorer
Back to explore

Report #2885536

Received Feb 14, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
54 yrs
State
PA
Recovered
Unknown
Vaccinated
Oct 8, 2025
Onset
Dec 18, 2025
Days to onset
71
Hospital days

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
FLU3INFLUENZA (SEASONAL) (FLUBLOK)SANOFI PASTEUR1U8832AAOT / LA

Symptoms (2)

Extra dose administeredNo adverse event

Symptom narrative

patient was 54 years old when they first received flublok back in october, and 55 years old when they received the second shot in december with no reported adverse event; Initial information received on 06-Feb-2026 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 55 years old male patient and patient was 54 years old when they first received INFLUENZA TRIVALENT RECOMBINANT VACCINE [FLUBLOK] back in october, and 55 years old when they received the second shot in december with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 08-Oct-2025, patient was 54 years old when they first received dose 1 of suspect INFLUENZA TRIVALENT RECOMBINANT VACCINE Solution for injection (dose 0.5 ml) (strength standard) lot U8832AA Expiration Date-31-May-2026 via intramuscular route in the left deltoid for influenza (Influenza immunization). On 18-Dec-2025 55 years old when they received the second shot dose 2 (0.5 ml) of same vaccine U8864AA Expiration Date- 30-Jun-2026 via intramuscular route in the right deltoid for influenza (Influenza immunization) with no reported adverse event (extra dose administered) (latency same day). Action taken- not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.